0002-5562 : Retevmo 160 mg Oral Tablet, Coated
| NDC: | 0002-5562 |
| Labeler: | Eli Lilly and Company |
| Product Type: | Human Prescription Drug |
| Drug Name: |  Retevmo |
| Dosage Form: | Oral Tablet, Coated |
| Application #: | NDA218160 |
| Rev. Date: |
NDC Package Codes:
- 0002-5562-60: 60 TABLET, COATED IN 1 BOTTLE (0002‑5562‑60)
Active Ingredients:
- Selpercatinib
Dosage Strength:
- 160 mg
Pharmaceutical Classes:
- Breast Cancer Resistance Protein Inhibitors [MoA]
- Cytochrome P450 2C8 Inhibitors [MoA]
- Cytochrome P450 3A Inhibitors [MoA]
- Kinase Inhibitor [EPC]
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]
- P-Glycoprotein Inhibitors [MoA]
- Rearranged during Transfection (RET) Inhibitors [MoA]
Related Products:
Based on records with the same trade name.- 0002-2980 Retevmo 80 mg Oral Capsule by Eli Lilly and Company
- 0002-3977 Retevmo 40 mg Oral Capsule by Eli Lilly and Company
- 0002-5340 Retevmo 40 mg Oral Tablet, Coated by Eli Lilly and Company
- 0002-6082 Retevmo 80 mg Oral Tablet, Coated by Eli Lilly and Company
- 0002-6120 Retevmo 120 mg Oral Tablet, Coated by Eli Lilly and Company
NDC QR Code
Scan the QR code below to easily reference this data in the future:
< Prev: 0002-5340Next: 0002-5800 >
Note: The RxChat NDC Database uses publicly available data from the FDA and the U.S. National Library of Medicine (NLM); The NLM is not responsible for the data presented and does not endorse or recommend this or any other product. While we make every effort to ensure that the information presented is accurate, you should assume that all results are unvalidated. To report any errors or inconsistencies please contact us.